Gianni Sava
Gianni Sava
Email verificata su
Citata da
Citata da
In vitro and in vivo evaluation of ruthenium (II)− arene PTA complexes
C Scolaro, A Bergamo, L Brescacin, R Delfino, M Cocchietto, G Laurenczy, ...
Journal of medicinal chemistry 48 (12), 4161-4171, 2005
Ruthenium antimetastatic agents
E Alessio, G Mestroni, A Bergamo, G Sava
Current Topics in Medicinal Chemistry 4 (15), 1525-1535, 2004
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates
A Bergamo, C Gaiddon, JHM Schellens, JH Beijnen, G Sava
Journal of inorganic biochemistry 106 (1), 90-99, 2012
Metal-based antitumour drugs in the post genomic era
PJ Dyson, G Sava
Dalton Transactions, 1929-1933, 2006
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
A Bergamo, G Sava
Dalton transactions 40 (31), 7817-7823, 2011
A review on usnic acid, an interesting natural compound
M Cocchietto, N Skert, P Nimis, G Sava
Naturwissenschaften 89, 137-146, 2002
Cis-and trans-dihalotetrakis (dimethyl sulfoxide) ruthenium (II) complexes (RuX2 (DMSO) 4; X= Cl, Br): synthesis, structure, and antitumor activity
E Alessio, G Mestroni, G Nardin, WM Attia, M Calligaris, G Sava, S Zorzet
Inorganic chemistry 27 (23), 4099-4106, 1988
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
S Leijen, SA Burgers, P Baas, D Pluim, M Tibben, E van Werkhoven, ...
Investigational new drugs 33, 201-214, 2015
Organometallic ruthenium-based antitumor compounds with novel modes of action
WH Ang, A Casini, G Sava, PJ Dyson
Journal of Organometallic Chemistry 696 (5), 989-998, 2011
Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen
G Sava, S Zorzet, C Turrin, F Vita, MR Soranzo, G Zabucchi, M Cocchietto, ...
Clinical Cancer Research 9 (5), 1898-1905, 2003
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A
G Sava, A Bergamo, S Zorzet, B Gava, C Casarsa, M Cocchietto, A Furlani, ...
European Journal of Cancer 38 (3), 427-435, 2002
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound
A Bergamo, A Masi, PJ Dyson, G Sava
International journal of oncology 33 (6), 1281-1289, 2008
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin
A Bergamo, R Gagliardi, V Scarcia, A Furlani, E Alessio, G Mestroni, ...
Journal of Pharmacology and Experimental Therapeutics 289 (1), 559-564, 1999
Ruthenium complexes can target determinants of tumour malignancy
A Bergamo, G Sava
Dalton Transactions, 1267-1272, 2007
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
G Sava, I Capozzi, K Clerici, G Gagliardi, E Alessio, G Mestroni
Clinical & experimental metastasis 16, 371-379, 1998
Metal-based antitumour drugs in the post-genomic era: what comes next?
G Sava, A Bergamo, PJ Dyson
Dalton Transactions 40 (36), 9069-9075, 2011
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation
M Bacac, ACG Hotze, K van der Schilden, JG Haasnoot, S Pacor, ...
Journal of inorganic biochemistry 98 (2), 402-412, 2004
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms
CA Vock, WH Ang, C Scolaro, AD Phillips, L Lagopoulos, ...
Journal of medicinal chemistry 50 (9), 2166-2175, 2007
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
A Bergamo, G Sava
Chemical Society Reviews 44 (24), 8818-8835, 2015
Ruthenium-based compounds and tumour growth control
G Sava, A Bergamo
International journal of oncology 17 (2), 353-418, 2000
Il sistema al momento non pu eseguire l'operazione. Riprova pi tardi.
Articoli 1–20